YKL-5-124 as a single agent and in combination with JQ1, demonstrated near-complete CDK7 engagement in spleen, liver as well as tumor tissues following one-week of treatment (Supplementary Figure 5C). The gene discussed is CDK7; the disease is neoplasm.